Alexander Andreev-Andrievskiy1, Mikhail Lomonosov2, Anfisa Popova3, Evgeniia Lagereva4, Pierre Clément5, Ramiz Salimov2, Dmitriy Golikov2. 1. Biology Faculty, M.V. Lomonosov Moscow State University, Moscow, Russia; MSU Institute of Mitoengineering LLC, Moscow, Russia; Institute for Biomedical problems RAS, Moscow, Russia. Electronic address: aandrievsky@gmail.com. 2. Aivix Ltd, Moscow, Russia. 3. Biology Faculty, M.V. Lomonosov Moscow State University, Moscow, Russia; MSU Institute of Mitoengineering LLC, Moscow, Russia; Institute for Biomedical problems RAS, Moscow, Russia. 4. MSU Institute of Mitoengineering LLC, Moscow, Russia; Institute for Biomedical problems RAS, Moscow, Russia. 5. Pelvipharm/INSERM U1179, Montigny-Le-Bretonneux, France.
Abstract
INTRODUCTION: Low sexual desire is a frequent sexual problem in women, with only one drug for the condition approved by the Food and Drug Administration. AIM: To evaluate the ability of a novel synthetic peptide, BP101, to facilitate sexual behavior after intranasal administration or infusion into certain brain areas in female rats. METHODS: Bilaterally ovariectomized female rats, primed with a suboptimal combination of estradiol benzoate (EB) and progesterone, were used as a model of low sexual motivation. Sexual behavior was tested with stud male rats after acute (experiment 1) or long-term (experiment 2) intranasal administration of BP101 or peptide infusion into the olfactory bulb, medial preoptic area, ventromedial hypothalamic nucleus, or ventral tegmental area (experiment 3). MAIN OUTCOME MEASURES: Frequency of solicitations (SF), as an indicator of sexual motivation in female rats, and lordosis frequency and ratio, as measurements of female consummatory sexual behavior. RESULTS: Acute intranasal BP101 administration moderately increased SF, with the highest tested dose of 300 μg/kg causing an 80% increase. Female rats receiving BP101 75 or 300 μg/kg daily on days 6 to 16 of the peptide administration displayed twofold higher SF compared with the placebo-treated animals, an increase comparable to optimally hormone-primed female rats. Infusion of BP101 1 and 5 μg per rat into the medial preoptic area, but not into the olfactory bulb, ventromedial hypothalamic nucleus, or ventral tegmental area, increased SF in female rats supplemented with EB 10 or 20 μg. The effect was relatively more pronounced in female rats receiving EB 10 μg (≈300%) compared with EB 20 μg (≈50%) with direct brain infusions. CONCLUSION: BP101 displays a potent stimulatory effect on sexual motivation in the female rat, and the medial preoptic area seems to be the site of its action. BP101 is effective in female rats receiving different hormone supplementations, making the present data generalizable to pre- and postmenopausal women with hypoactive sexual desire. Andreev-Andrievskiy A, Lomonosov M, Popova A, et al. BP101 Peptide Promotes Female Sexual Receptivity in the Rat. J Sex Med 2017;14:336-346.
INTRODUCTION:Low sexual desire is a frequent sexual problem in women, with only one drug for the condition approved by the Food and Drug Administration. AIM: To evaluate the ability of a novel synthetic peptide, BP101, to facilitate sexual behavior after intranasal administration or infusion into certain brain areas in female rats. METHODS: Bilaterally ovariectomized female rats, primed with a suboptimal combination of estradiol benzoate (EB) and progesterone, were used as a model of low sexual motivation. Sexual behavior was tested with stud male rats after acute (experiment 1) or long-term (experiment 2) intranasal administration of BP101 or peptide infusion into the olfactory bulb, medial preoptic area, ventromedial hypothalamic nucleus, or ventral tegmental area (experiment 3). MAIN OUTCOME MEASURES: Frequency of solicitations (SF), as an indicator of sexual motivation in female rats, and lordosis frequency and ratio, as measurements of female consummatory sexual behavior. RESULTS: Acute intranasal BP101 administration moderately increased SF, with the highest tested dose of 300 μg/kg causing an 80% increase. Female rats receiving BP101 75 or 300 μg/kg daily on days 6 to 16 of the peptide administration displayed twofold higher SF compared with the placebo-treated animals, an increase comparable to optimally hormone-primed female rats. Infusion of BP101 1 and 5 μg per rat into the medial preoptic area, but not into the olfactory bulb, ventromedial hypothalamic nucleus, or ventral tegmental area, increased SF in female rats supplemented with EB 10 or 20 μg. The effect was relatively more pronounced in female rats receiving EB 10 μg (≈300%) compared with EB 20 μg (≈50%) with direct brain infusions. CONCLUSION:BP101 displays a potent stimulatory effect on sexual motivation in the female rat, and the medial preoptic area seems to be the site of its action. BP101 is effective in female rats receiving different hormone supplementations, making the present data generalizable to pre- and postmenopausal women with hypoactive sexual desire. Andreev-Andrievskiy A, Lomonosov M, Popova A, et al. BP101 Peptide Promotes Female Sexual Receptivity in the Rat. J Sex Med 2017;14:336-346.